S100. Efficacy and Safety of Brexanolone IV Across Phase 2/3 Studies: A First-In-Class GABAA Receptor Positive Allosteric Modulator for Postpartum Depression

Samantha Meltzer-Brody,Stephen Kanes,Robert Riesenberg,C Neill Epperson,Kristina Deligiannidis,David Rubinow,Haihong Li,Christine Clemson,Helen Colquhoun

doi:10.1016/j.biopsych.2018.02.991

S100. Efficacy and Safety of Brexanolone IV Across Phase 2/3 Studies: A First-In-Class GABAA Receptor Positive Allosteric Modulator for Postpartum Depression

Samantha Meltzer-Brody, Stephen Kanes + Show 7 more

https://doi.org/10.1016/j.biopsych.2018.02.991

Copy DOI

Journal: Biological psychiatry	Publication Date: Apr 9, 2018
Citations: 2

Affiliation: University of North Carolina at Chapel Hill, Presage Biosciences (United States), Atlanta Center for Medical Research, University of Pennsylvania, Zucker Hillside Hospital

#GABAA Receptor Positive Allosteric Modulator #Postpartum Depression + Show 7 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Postpartum depression (PPD) is a mood disorder that can have serious consequences for the mother and family. Brexanolone iv (USAN; formerly SAGE-547 Injection) showed antidepressant effects in preclinical studies, early Phase 2 studies, and first-ever Phase 3 studies in PPD.

Full Text